EE05515B1 - 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks - Google Patents
1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviksInfo
- Publication number
- EE05515B1 EE05515B1 EEP200200390A EEP200200390A EE05515B1 EE 05515 B1 EE05515 B1 EE 05515B1 EE P200200390 A EEP200200390 A EE P200200390A EE P200200390 A EEP200200390 A EE P200200390A EE 05515 B1 EE05515 B1 EE 05515B1
- Authority
- EE
- Estonia
- Prior art keywords
- treatment
- benzimidazoles
- diar
- diseases associated
- microglial activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10002898 | 2000-01-14 | ||
PCT/EP2001/000334 WO2001051473A1 (de) | 2000-01-14 | 2001-01-12 | 1,2-diarylbenzimidazole zur behandlung von krankungen die mit einer microglia-aktivierung assoziiert sind |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200390A EE200200390A (et) | 2003-10-15 |
EE05515B1 true EE05515B1 (et) | 2012-02-15 |
Family
ID=7628535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200390A EE05515B1 (et) | 2000-01-14 | 2001-01-12 | 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1246808B1 (ru) |
JP (1) | JP2003523961A (ru) |
KR (1) | KR100703908B1 (ru) |
CN (1) | CN1301975C (ru) |
AT (1) | ATE520669T1 (ru) |
AU (1) | AU782993B2 (ru) |
BG (1) | BG65858B1 (ru) |
BR (1) | BR0107628A (ru) |
CA (1) | CA2396227C (ru) |
CY (1) | CY1112962T1 (ru) |
CZ (1) | CZ303726B6 (ru) |
DK (1) | DK1246808T3 (ru) |
EA (1) | EA006302B1 (ru) |
EE (1) | EE05515B1 (ru) |
ES (1) | ES2372026T3 (ru) |
HR (1) | HRP20020664B1 (ru) |
HU (1) | HU228366B1 (ru) |
IL (2) | IL150150A0 (ru) |
ME (1) | MEP13308A (ru) |
MX (1) | MXPA02005742A (ru) |
NO (1) | NO326408B1 (ru) |
NZ (1) | NZ519326A (ru) |
PL (1) | PL209573B1 (ru) |
PT (1) | PT1246808E (ru) |
RS (1) | RS51860B (ru) |
SI (1) | SI1246808T1 (ru) |
SK (1) | SK287527B6 (ru) |
TW (1) | TWI287005B (ru) |
UA (1) | UA75589C2 (ru) |
WO (1) | WO2001051473A1 (ru) |
ZA (1) | ZA200206470B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
US6903126B2 (en) | 2001-07-09 | 2005-06-07 | Schering Ag | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
DE10135050A1 (de) * | 2001-07-09 | 2003-02-06 | Schering Ag | 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
DE10207844A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
US6962932B2 (en) | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
DE10207843A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
SE0302573D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302570D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
BRPI0515897A (pt) | 2004-09-24 | 2008-08-12 | Astrazeneca Ab | composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto |
TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
JP5255994B2 (ja) * | 2008-11-04 | 2013-08-07 | 国立大学法人 岡山大学 | 核内受容体リガンド |
US9382226B2 (en) | 2010-07-21 | 2016-07-05 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
CN102382102B (zh) * | 2010-09-06 | 2014-01-08 | 中国科学院广州生物医药与健康研究院 | 一种酰胺类化合物 |
CN110698408B (zh) * | 2012-02-17 | 2021-01-05 | 奇尼塔病毒性出血热有限责任公司 | 用于治疗沙粒病毒感染的抗病毒药物 |
WO2014044611A1 (en) | 2012-09-20 | 2014-03-27 | Bayer Pharma Aktiengesellschaft | 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration |
ES2830447T3 (es) * | 2015-12-15 | 2021-06-03 | Univ Leland Stanford Junior | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación |
RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4430502A (en) * | 1982-08-13 | 1984-02-07 | The Upjohn Company | Pyridinyl substituted benzimidazoles and quinoxalines |
ATE163290T1 (de) * | 1991-06-24 | 1998-03-15 | Neurosearch As | Imidazol-verbindungen, verfahren zu ihrer herstellung und ihre anwendung |
MX9203323A (es) * | 1991-07-11 | 1994-07-29 | Hoechst Ag | El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales. |
DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE4330959A1 (de) * | 1993-09-09 | 1995-03-16 | Schering Ag | Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
IL113472A0 (en) * | 1994-04-29 | 1995-07-31 | Lilly Co Eli | Non-peptidyl tachykinin receptor antogonists |
US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
AU6966696A (en) * | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
AU2207897A (en) * | 1996-03-11 | 1997-10-01 | Eli Lilly And Company | Methods of treating or preventing interstitial cystitis |
-
2001
- 2001-01-12 PT PT01915133T patent/PT1246808E/pt unknown
- 2001-01-12 DK DK01915133.1T patent/DK1246808T3/da active
- 2001-01-12 BR BR0107628-0A patent/BR0107628A/pt not_active IP Right Cessation
- 2001-01-12 TW TW090100751A patent/TWI287005B/zh not_active IP Right Cessation
- 2001-01-12 AU AU42332/01A patent/AU782993B2/en not_active Ceased
- 2001-01-12 CN CNB018037666A patent/CN1301975C/zh not_active Expired - Fee Related
- 2001-01-12 RS YU45702A patent/RS51860B/sr unknown
- 2001-01-12 CA CA2396227A patent/CA2396227C/en not_active Expired - Fee Related
- 2001-01-12 SK SK1000-2002A patent/SK287527B6/sk not_active IP Right Cessation
- 2001-01-12 PL PL356091A patent/PL209573B1/pl unknown
- 2001-01-12 EE EEP200200390A patent/EE05515B1/xx not_active IP Right Cessation
- 2001-01-12 CZ CZ20022420A patent/CZ303726B6/cs not_active IP Right Cessation
- 2001-01-12 WO PCT/EP2001/000334 patent/WO2001051473A1/de active IP Right Grant
- 2001-01-12 ME MEP-133/08A patent/MEP13308A/xx unknown
- 2001-01-12 ES ES01915133T patent/ES2372026T3/es not_active Expired - Lifetime
- 2001-01-12 JP JP2001551855A patent/JP2003523961A/ja active Pending
- 2001-01-12 AT AT01915133T patent/ATE520669T1/de active
- 2001-01-12 IL IL15015001A patent/IL150150A0/xx unknown
- 2001-01-12 EA EA200200742A patent/EA006302B1/ru not_active IP Right Cessation
- 2001-01-12 SI SI200131004T patent/SI1246808T1/sl unknown
- 2001-01-12 NZ NZ519326A patent/NZ519326A/en not_active IP Right Cessation
- 2001-01-12 HU HU0204011A patent/HU228366B1/hu not_active IP Right Cessation
- 2001-01-12 KR KR1020027009085A patent/KR100703908B1/ko not_active IP Right Cessation
- 2001-01-12 MX MXPA02005742A patent/MXPA02005742A/es active IP Right Grant
- 2001-01-12 EP EP01915133A patent/EP1246808B1/de not_active Expired - Lifetime
- 2001-12-01 UA UA2002086720A patent/UA75589C2/uk unknown
-
2002
- 2002-06-11 IL IL150150A patent/IL150150A/en not_active IP Right Cessation
- 2002-06-13 BG BG106821A patent/BG65858B1/bg unknown
- 2002-07-12 NO NO20023362A patent/NO326408B1/no not_active IP Right Cessation
- 2002-08-13 ZA ZA200206470A patent/ZA200206470B/xx unknown
- 2002-08-13 HR HR20020664A patent/HRP20020664B1/xx not_active IP Right Cessation
-
2011
- 2011-11-16 CY CY20111101101T patent/CY1112962T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05515B1 (et) | 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks | |
TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
EE05419B1 (et) | Asendatud oksasolidinoonid kombineeritud raviks | |
PT1119543E (pt) | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y | |
ATE429233T1 (de) | Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten | |
CY1107465T1 (el) | Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
ES2038074A1 (es) | Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos. | |
IT1318667B1 (it) | Medicamento antinfiammatorio. | |
ATE231849T1 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
TR199701536T1 (xx) | Benzimidazollerin, l�seminin tedavisi i�in bir ila� �retilmesinde kullan�m�. | |
CY1111900T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda) | |
NO20031410L (no) | Anvendelse av distamycinderivater for fremstilling av medikamenter | |
SE0004101D0 (sv) | New use | |
DE60315288D1 (de) | Cyanoguanidin prodrugs | |
BR0014687A (pt) | Compostos de taxano pentacìclico | |
HRP20040186B1 (en) | Use of lhrh-antagonists for the improvement of t-cell mediated immunity | |
PT1404656E (pt) | Derivados de benzimidazole para o tratamento de doencas associadas a activacao de microglia como doencas inflamatorias, alergicas, infecciosas ou autoimunes | |
SE0300535D0 (sv) | Treatment of burns | |
CO5200836A1 (es) | Derivados de bencimidazol sustituidos con arilsulfonamida, procedimiento para su preparacion y su empleo como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB1A | Change in the ownership or in the address of the owner | ||
MM4A | Lapsed by not paying the annual fees |
Effective date: 20150112 |